Clinical Trials Logo

Clinical Trial Summary

This study collects data on microbiological, genetic and environmental factors, as well as lung function parameters (e.g. spirometry, body plethysmography, lung-MRI) to assess the complex interaction of predisposing risk factors for impaired lung development and respiratory diseases.


Clinical Trial Description

Background: Lung development and growth is a complexly orchestrated process starting prenatally in the first embryonic weeks, and ending, with the last important stages of alveolarization from the 24th week onwards. By the time of birth, around one third of the total amount of alveoli has developed, while the rest develops during infancy and childhood. After birth, lung volume, airways and the gas-exchanging surface increase by a multiple, reaching the maximum lung size at around 25 years of age. A comprehensive understanding of lung growth and development is crucial in order to understand the pathophysiology of lung diseases. During childhood and ongoing lung growth, an important amount of respiratory diseases might develop. Objectives: Longitudinal assessment of lung growth and development, to examine respiratory morbidity such as Asthma and allergy, and the complex relationship between associated Risk factors mainly genetic predisposition and environmental factors on both lung development and subsequent respiratory morbidity, Therefore, longitudinal data on lung function and structure, on respiratory morbidity and on genetic, immunological, microbiological and environmental risk factors will be collected. Methods: Recruitment and participation: Participants will be recruited antenatal through advertisement placed at gynaecological Hospital in Bern and by obstetricians or midwives. Interested participants can get further information about the study by telephone from study nurses, as well as during the baseline visit at the University Children's Hospital in Bern, respectively. Mothers with a high risk of a preterm delivery will be informed by clinical Investigators at the Department of Obstetrics of the University Hospital Bern. Preterm infants, which receive ventilatory support over a long period are at Risk for chronical lung diseases in early childhood, named bronchopulmonary dysplasia (BPD). The recruitment of this infants will take place at the neonatology intensive care unit by clinical Investigators. On average 40 healthy children, 40 preterm children and 20 infants from risk pregnancies will be recruited as participants of the BILD cohort each year for Study Phase I. At 3, 6, 9, 12, 15 years and once after the 16th year of age the parents/participants will be asked again, if they would like to participate at the follow-up visits at the University Children's Hospital in Bern for the subsequent Study Phases II and III. Information collected: Lung function data: - Tidal breathing parameters (minute ventilation, respiratory rate, tidal volume, tidal expiratory flow, tidal inspiratory flow, time to peak expiratory flow) averaged over 100 breaths. - Multiple breath washout (FRC, LCI, moment ratios) and single breath washout (molar mass) - Fractional exhaled nitric oxide (marker of airway inflammation) - Spirometric forced expiratory volume loops (FVC, FEV1, PEF, MEF50) - Body plethysmography (airway resistance, lung volumes: TLC, FRC, RV) - Respiratory Rate over 60 seconds - Interrupter resistance measurement (RINT) - Volatile organic compounds - Forced oscillation technique (FOT) - Electrical impedance tomography (EIT) - Impedance plethysmography (IP) Microbiological data: - Nasal swabs (respiratory virus and bacterial diagnostics, as well as host transcriptome Analysis) - Pharyngeal swabs (bacterial colonization and microbiota Analysis) - Anterior nasal and oropharyngeal swabs (viral, bacterial and host transcriptome Analysis) - Nasal brush - Sputum (to analyse the neutrophils) Cord blood (mononuclear cells (CBMC) (e.g. lymphocytes)which regulate the innate and adaptive immunity) Blood count (hemoglobin concentration, hematocrit, leukocyte number, lymphocyte number, lymphocyte count, eosinophil count, basophil count, monocyte count, promyelocyte count, myelocyte count, platelet count, immunoglobulin E Level, Interleukins, Granulocyte-Monocyte-Colony Forming Unit, Tumor Necrosis Factor alpha, Interferon gamma and Interferon lambda) Urin (to estimate the tobacco exposure during pregnancy (amount of Cotinine) and the content of caffeine and Steroid profile) Lung function MRI: functional and structural images of the lung Environmental pollution (Level of particulate matter <10um, Nitrogen dioxide, ozone and particulate matter <2.5um) Skin-Prick Test (test for pollen, trees, house dust mite, cat and dog) Questionnaires (to assess quality of life) Medical history (information on respiratory Symptoms, pulmonary exacerbations, hospitalisations and regular therapy) Study database: All study data is recorded in an Access-database with SQL Servers by electronic Case Report Forms. The database is accordant to the HFG and was adapted together with the CTU. Funding: Schweizerischer Nationalfonds (SNF) and Departement Lehre und Forschung of the Inselspital Bern. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT04286464
Study type Observational
Source University Hospital Inselspital, Berne
Contact
Status Enrolling by invitation
Phase
Start date September 2003
Completion date January 2051

See also
  Status Clinical Trial Phase
Completed NCT05029518 - 3-Way Crossover Study to Compare the PK (Pharmokinetics) and to Evaluate the Effect of Food on the Bioavailability Phase 1
Completed NCT05001152 - Taste Assessment of Ozanimod Phase 1
Completed NCT04493255 - A Study to Determine the Metabolism and Elimination of [14C]E7090 in Healthy Male Participants Phase 1
Completed NCT03457649 - IV Dose Study to Assess the Safety, Tolerability, PK, PD and Immunogenicity of ARGX-113 in Healthy Volunteers Phase 1
Completed NCT00995891 - Collection of Blood, Bone Marrow, and Buccal Mucosa Samples From Healthy Volunteers for Center for Human Immunology, Autoimmunity, and Inflammatory Diseases (CHI) Laboratory Research Studies
Completed NCT05043766 - Evaluation of Oral PF614 Relative to OxyContin Phase 1
Completed NCT05050318 - Annual Study for Collection of Serum Samples in Children and Older Adults Receiving the 2021-2022 Formulations of Fluzone Quadrivalent Vaccine and Fluzone High-Dose Quadrivalent Vaccine, Respectively Phase 4
Completed NCT04466748 - A Multiple Ascending Dose Pharmacology Study of Anaprazole in Healthy Chinese Subjects Phase 1
Completed NCT00746733 - Vyvanse and Adderall XR Given Alone and in Combination With Prilosec OTC Phase 1
Recruiting NCT05929651 - Study of Immunogenicity and Safety of MenQuadfi® as a Booster Vaccine in Toddlers 12 to 23 Months, Regardless of the Quadrivalent Meningococcal Conjugate Vaccine Used for Priming in Infancy Phase 4
Completed NCT05954039 - Evaluation of the Efficacy of a Dietary Supplement on Hair Loss and Hair Aspect N/A
Completed NCT05045716 - A Study of Subcutaneous Lecanemab in Healthy Participants Phase 1
Active, not recruiting NCT02747927 - Efficacy, Safety and Immunogenicity of Takeda's Tetravalent Dengue Vaccine (TDV) in Healthy Children Phase 3
Completed NCT05533801 - A Study to Demonstrate the Bioequivalence of Lecanemab Supplied in Vials and a Single-Use Auto-Injector (AI) in Healthy Participants Phase 1
Not yet recruiting NCT03931369 - Adaptation of Thirst to a Single Administration of Tolvaptan (TOLVATHIRST) Phase 2
Completed NCT03279146 - A Single Dose Study Evaluating PK of TXL Oral Formulations in Healthy Subjects Phase 1
Completed NCT06027437 - A Study to Assess the Relative Biological Availability and the Effect of Food on the Drug Levels of Danicamtiv in Healthy Adult Participants Phase 1
Recruiting NCT05619874 - Effects of Two Virtual HIFCT Programs in Adults With Abdominal Obesity N/A
Completed NCT05553418 - Investigational On-body Injector Clinical Study N/A
Completed NCT04092712 - Study Evaluating Pharmacokinetics and Mass Balance of [14C]-CTP-543 in Healthy Adult Male Volunteers Phase 1